Moshe Weinstein CEO
Moshe joined Moebius in December 2015, and brings with him over 15 years of business experience. Prior to joining Moebius, Moshe spent 7 years at Novartis in the US and Latin America where he held positions of increasing responsibility in business development & licensing, sales, marketing and commercial management. Prior to Novartis, Moshe served as a consultant for PricewaterhouseCoopers. Moshe earned an MBA from INSEAD, and has a bachelors in business & management from Yeshiva University in New York.
Dr. Yaniv Dolev Founder & COOYaniv founded Moebius in 2008 and served as the company’s CEO from its foundation until December 2015. Yaniv was responsible for the development and successful clinical trial of MM-II, and led the company through a series of fundraising rounds. Yaniv trained as a Veterinary Surgeon at the Faculty of Veterinary Science, National University of La Plata, Argentina, where he specialized in equine orthopedics. He earned an M.B.A. from the School of Macro-Economic Studies, Buenos Aires, Argentina.
Prof. Chezy Barenholz Inventor & Board MemberYechezkel “Chezy” Barenholz, Ph.D. is the head of the Laboratory of Membrane and Liposome Research at the Department of Biochemistry, at the Hebrew University, Hadassah Medical School, Jerusalem, Israel. Dr. Barenholz is a world renowned specialist in lipids and membranes, and is on the Editorial Boards of Chemistry and Physics of Lipids and the Journal of Liposome Research. He is one of the key inventors of DOXIL, a liposomal formulation of doxorubicin for cancer treatment, marketed by Johnson & Johnson.
For more Information please visit:
Moebius Medical Ltd. is an innovative clinical stage biotechnology company that is developing novel pain relief treatments for osteoarthritis. The company is based on a patent-protected technology that was licensed from the Hebrew University of Jerusalem, the Technion Institute and Hadassah Medical Center. The Company’s lead product, MM-II, is a patent-protected intraarticular biolubricant injection for treatment of mild to moderate symptomatic knee osteoarthritis (OA). The company has been funded by RAD Biomed, PixVine Capital – a Singapore-based early stage VC fund, and Yissum – the technology transfer company of the Hebrew University of Jerusalem.
MM-II brings a novel option to osteoarthritis knee pain sufferers looking for effective non-surgical solutions, and has demonstrated its ability to reduce osteoarthritic pain and its superiority over the standard-of-care in a first-in-man double blinded, randomized, controlled trial.MM-II is a liposomal injection that relieves knee pain by lubricating joint and reducing joint friction and wear. MM-II leverages the physical properties of a proprietary large multilamellar “onion like” liposome whose bilayers are composed of 2 known phospholipids.
HIGHLIGHTS OF CLINICAL RESULTS:
A first-in-man, randomized, controlled, double-blinded study was conducted in mild to moderate symptomatic knee OA patients comparing MM-II to hyaluronic acid, the standard of care. A single injection of MM-II showed faster and better improvement in pain and activity than hyaluronic acid, the standard of care. Results were presented at recent conferences of the American Academy of Orthopedic Surgeons, Osteoarthritis Research Society International, and American College of Rheumatology.